Posted by Michael Wonder on 14 Nov 2023
Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer
14 November 2023 - Approval based on results from TOPAZ-1 global Phase 3 trial and a Chinese patient cohort which showed a 22% reduction in the risk of death versus chemotherapy alone.
AstraZeneca’s Imfinzi (durvalumab) has been approved in China for the first-line treatment of adult patients with locally advanced or metastatic biliary tract cancer in combination with chemotherapy (gemcitabine and cisplatin).
